Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Prevention of Further Absorption of Poison

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing Clinical Reasoning in Hospice and Palliative Medicine Fellows.

Journal of palliative medicine·2026

Same author

A Responsibly-Minded Approach to Virtual Echocardiography Training of Non-Specialists in Haiti and Beyond.

Academic medicine : journal of the Association of American Medical Colleges·2026

Same author

Advancing Race-Conscious Medicine: Using Debate to Promote Critical Appraisal of Race in Medical Literature.

Journal of general internal medicine·2026

Same author

Implementing an Innovative Transgender and Gender Diverse Health Curriculum for Physician Assistant (PA) Students.

AACE endocrinology and diabetes·2026

Same author

Impact of a Novel Curriculum on Internal Medicine Residents' Management of Outpatient Hypertensive Urgencies.

Journal of general internal medicine·2024

Same author

Achieving adherence to positive airway pressure in commercial drivers using an employer-mandated remote management programme.

ERJ open research·2024

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Cannabinoid hyperemesis relieved by compulsive bathing.

Yoon Hee Chang¹, Donna M Windish

¹Yale Internal Medicine Primary Care Office, 64 Robbins Street, Waterbury, CT 06708, USA. Yoonhee.chang@gmail.com

Mayo Clinic Proceedings

|January 6, 2009

Summary

Cannabinoid hyperemesis syndrome, linked to long-term marijuana use, causes severe vomiting and compulsive hot bathing. This may be due to cannabinoid receptors affecting gut motility and thermoregulation.

More Related Videos

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Area of Science:

Gastroenterology
Pharmacology
Endocrinology

Background:

Cannabinoid hyperemesis syndrome (CHS) is a condition associated with chronic marijuana use.
It is characterized by cyclical nausea, vomiting, and compulsive bathing behaviors.
The underlying mechanisms of CHS are not fully understood.

Observation:

This report details two cases of CHS.
Patients presented with severe, intractable vomiting.
A consistent finding was the compulsive need for hot showers or baths.

Findings:

Cannabinoid type 1 receptors in the gut may inhibit gastrointestinal motility, potentially causing hyperemesis.
Endocannabinoids' role in thermoregulation might explain the compulsive hot bathing behavior.
These findings link specific physiological effects of cannabinoids to CHS symptoms.

Implications:

Understanding these mechanisms can aid in diagnosing and managing CHS.
This research highlights potential adverse effects of long-term marijuana use.
Further investigation into cannabinoid receptor function is warranted.